Rezultati pretrage - Peyrin-Biroulet, L

Does hyperhomocysteinaemia contribute to gastric carcinogenesis in Helicobacter pylori infected patients? od Peyrin‐Biroulet, L, Guéant, Jean‐Louis

Preuzmi cijeli tekst Preuzmi cijeli tekst

Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD od Sebastian, S, Gonzalez, H A, Peyrin-Biroulet, L

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

PPARγ as a new therapeutic target in inflammatory bowel diseases od Dubuquoy, L, Rousseaux, C, Thuru, X, Peyrin‐Biroulet, L, Romano, O, Chavatte, P, Chamaillard, M, Desreumaux, P

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventiona... od Colombel, J.‐F., Jharap, B., Sandborn, W. J., Feagan, B., Peyrin‐Biroulet, L., Eichner, S. F., Robinson, A. M., Mostafa, N. M., Zhou, Q., Thakkar, R. B.

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce od Magro, F, Rahier, J-F, Abeu, C, MacMahon, E, Hart, A, van der Woude, C J, Gordon, H, Adamina, M, Viget, N, Vavricka, S, Kucharzik, T, Leone, S, Siegmund, B, Danese, S, Peyrin-Biroulet, L

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

The management of iron deficiency in inflammatory bowel disease – an online tool developed by the RAND/UCLA appropriateness method od Reinisch, W, Chowers, Y, Danese, S, Dignass, A, Gomollón, F, Haagen Nielsen, O, Lakatos, P L, Lees, C W, Lindgren, S, Lukas, M, Mantzaris, G J, Michetti, P, Moum, B, Peyrin-Biroulet, L, Toruner, M, Woude, J, Weiss, G, Stoevelaar, H

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease od Marthey, L., Mateus, C., Mussini, C., Nachury, M., Nancey, S., Grange, F., Zallot, C., Peyrin-Biroulet, L., Rahier, J. F., Bourdier de Beauregard, M., Mortier, L., Coutzac, C., Soularue, E., Lanoy, E., Kapel, N., Planchard, D., Chaput, N., Robert, C., Carbonnel, F.

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY od Peyrin-Biroulet, L, Loftus, E V, Danese, S, Vermeire, S, Sandborn, W J, Fogel, R, Nijhawan, S, Kempinski, R, Filip, R, Hospodarskyy, I, McNally, J, Yun, C, Zhao, S, Liu, X, Tasset, C, Besuyen, R, Watanabe, M, Schreiber, S, Rogler, G, Hibi, T, Feagan, B G

Preuzmi cijeli tekst Preuzmi cijeli tekst

A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY od Panaccione, R, Ferrante, M, Feagan, B G, Sandborn, W, Panes, J, Peyrin-Biroulet, L, Colombel, J, Schreiber, S, Dubinsky, M, Baert, F, Hisamatsu, T, Neimark, E, Huang, B, Liao, X, Song, A, Berg, S, Duan, W, Pang, Y, Pivorunas, V, Kligys, K, Wallace, K, D’Haens, G

Preuzmi cijeli tekst Preuzmi cijeli tekst